Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH

JW Pharmaceutical

Status and phase

Completed

Phase 4

Conditions

Benign Prostatic Hypertrophy

Treatments

Drug: Silodosin

Study type

Interventional

Funder types

Industry

Identifiers

NCT01260129

CWP-SDS-401

Details and patient eligibility

About

Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety.

Full description

Silodosin is a highly selective α1A-adrenoceptor antagonist for the treatment of the signs and symptoms of BPH. 4mg Silodosin twice daily has been approved in Asia including Japan and Korea. In US, 8mg Silodosin once daily with the FDA approval is already available. Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety. The study used double-blind, random assignment in Korean men with signs and symptoms of BPH for 12 weeks.

Enrollment

424 patients

Sex

Male

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have been diagnosed with BPH through digital rectal exam or ultrasonographic findings and meet the following criteria.

Outpatients aged 50 or over
Patients with a total I-PSS score of 8 or higher and a QoL score of 3 or higher
Patients with a prostate volume measured by transabdominal ultrasonography, or TRUS of 20 ml or greater
Patients with a maximum urinary flow rate (Qmax_) of 15ml/sec or below (whose a void urinary volume of 120ml or greater)

Exclusion criteria

Patients with a residual urinary volume of 200ml or greater
Patients with a history of prostatectomy
Patients with a history of intrapelvic radiation therapy
Patients with a history of prostatic hyperthermia
Patients with prostate cancer or suspected prostate cancer
Patients with complications considered likely to affect urinary passing such as neurogenic bladder, bladder calculus and active urinary tract infection. UTI
Patients conducting self-catheterization
Patients with renal impairment (serum creatinine of 3.0 mg/dl or greater)
Patients with severe heptic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma) or with a total bilirubin of 3.0mg/dL or greater or AST/ALT 2.5 times higher than normal level
Patients with history of severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months
Patients with a history of an allergy to α-blockers
Patients with orthostatic hypotension at around screening visit
Patients with an experience of other investigational product treatments within 4 weeks form screening visit.
Patients with a PSA of 10 or over, Patients with tumor identified by a prostate biopsy with a PSA of 4 or over (For patients taking 5α-reductase inhibitors for more than 3 months are presumed to have double than their actual PSA levels.)
Patients who have taken unstable doses of antidepressants within the 3 months or who are expected to take unstable doses during the study
Patients who have taken alpha blockers within the 2 weeks from the start of the therapy
Patients who have taken unstable doses of 5α-reductase inhibitors within the 3 months from the start of the therapy or who are expected to take unstable doses during the study.
Patients disqualified by the investigator.